CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −2,813 | $351.80 | $990K | 237,930 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −3,673 | $353.32 | $1.3M | 234,257 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −6,717 | $354.78 | $2.4M | 227,540 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −3,476 | $355.66 | $1.2M | 224,064 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −12,418 | $356.62 | $4.4M | 211,646 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −15,869 | $357.67 | $5.7M | 195,777 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −45,044 | $358.70 | $16.2M | 150,733 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −21,254 | $359.50 | $7.6M | 129,479 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −3,680 | $360.63 | $1.3M | 125,799 |
| 2026-08-03 | Rosenberg Aaron Chief Financial Officer | Sale | −1,157 | $312.72 | $362K | 0 |
| 2026-07-30 | Lee Chan Henry SVP, General Counsel | Sale | −1,044 | $323.69 | $338K | 0 |
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +514 | $194.47 | $100K | 514 |
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +665 | $213.32 | $142K | 1,179 |
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +490 | $159.03 | $78K | 1,669 |
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −1,669 | $325.00 | $542K | 0 |
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −6,682 | 10,556 | ||
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −8,645 | 71,123 | ||
| 2026-07-22 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −6,370 | 98,930 | ||
| 2026-07-21 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −15,379 | $316.26 | $4.9M | 46,018 |
| 2026-07-21 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −20,029 | $316.91 | $6.3M | 25,989 |
Page 5 of 71 · 1,406 trades